Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
16-30 of 2287 results
aTyr Pharma's Resolaris secures FDA fast track status
The US Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma's Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B).
Drug Research > Drug Delivery > News
Mallinckrodt to pay $100m to settle US charges on drug pricing
By PBR Staff Writer
Mallinckrodt has agreed to pay $100m to settle the US Federal Trade Commission (FTC) and state charges that it illegally maintained its monopoly of specialty drug used to treat infants.
Drug Research > Drug Delivery > News
MonoSol Rx files patent infringement case against BioDelivery Sciences International
MonoSol Rx has filed a patent infringement case against BioDelivery Sciences International (BDSI) for infringement of U.S. Patent No. 8,765,167 (the ‘167 patent), which is entitled “Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions.”
Drug Research > Drug Delivery > News
Kalobios secures green light from FDA to proceed with Chagas disease drug
KaloBios Pharmaceuticals announced positive guidance from a recent meeting with with the US Food and Drug Administration (FDA) to discuss the development plans for benznidazole to treat Chagas disease, a neglected tropical disease.
Drug Research > Drug Delivery > News
RaNA Therapeutics acquires Messenger RNA Platform from Shire
RaNA Therapeutics has acquired the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire.
Drug Research > Drug Delivery > News
Cannabics Pharmaceuticals unveils new dosage of 5mg THC Cannabis capsule
Cannabics Pharmaceuticals has unveiled a new dosage of 5mg THC Cannabis capsule to treat cancer patients suffering from Cachexia and Anorexia Syndrome.
Drug Research > Drug Delivery > News
Factor One Source Pharmacy to buy Fast Access Specialty Therapeutics
Factor One Source Pharmacy (FOSRx) has agreed to acquire Fast Access Specialty Therapeutics (F.A.S.T.) for a combination of cash and stock.
Drug Research > Drug Delivery > News
TetraLogic sells SMAC Mimetic and HDAC Inhibitor assets to Medivir
TetraLogic Pharmaceuticals has completed the sale of its SMAC Mimetic and HDAC Inhibitor assets to Medivir.
Drug Research > Drug Delivery > News
Clinigen to distribute BioQ Pharma’s pain relief drug in Europe
Clinigen Group’s Idis Global Access (GA) division has signed a supply and distribution agreement with ready-to-use infusible products developer BioQ Pharma.
Drug Research > Drug Delivery > News
Baxter to acquire Claris Injectables for $625m
By PBR Staff Writer
US drug maker Baxter International has agreed to acquire Claris Lifesciences' injectables business for about $625m.
Drug Research > Drug Delivery > News
Proton Partners to build new cancer center in Reading, UK
Proton Partners International has secured formal planning permission to establish a new cancer treatment center in Reading, Berkshire, UK.
Drug Research > Drug Delivery > News
Cardiome Pharma launches Xydalba (dalbavancin) in UK
Cardiome Pharma has launched XYDALBA for injection, a second-generation, semi-synthetic lipoglycopeptide, in the UK earlier than expected.
Drug Research > Drug Delivery > News
Endo returns rights for BELBUCA to BioDelivery Sciences International
Endo International has entered into an agreement with its partner, BioDelivery Sciences International (BDSI), to return the BELBUCA (buprenorphine) buccal film product to BDSI.
Drug Research > Drug Delivery > News
GlobalData says NSCLC market will increase to $26.71bn by 2025
Research and consulting firm GlobalData said the non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to increase to $26.71bn by 2025 from $6.21bn in 2015, representing a very strong compound annual growth rate of 15.7%.
Drug Research > Drug Delivery > News
FDA approves DARZALEX for relapsed multiple myeloma
Genmab has secured approval from the US Food and Drug Administration (FDA) to use DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug Research > Drug Delivery > News
16-30 of 2287 results